Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 9/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28612826 | 0.94 | ADRA1A (0.54) | ADRA1ASLC18A3KCNH2HRH3KEAP1 | |
| SCHEMBL2933131 | 0.91 | HRH3 (0.55) | ADRA1AKCNH2HRH3SIGMAR1 | |
| SCHEMBL26962906 | 0.82 | ADRA1A (0.46) | ADRA1A | |
| SCHEMBL18186148 | 0.82 | ADRA1A (0.52) | ADRA1AHRH3NOTUM | |
| SCHEMBL2573737 | 0.82 | ADRA1A (0.52) | ADRA1AHRH3NOTUM | |
| SCHEMBL26962994 | 0.82 | FAAH (0.45) | ADRA1A | |
| SCHEMBL2563590 | 0.82 | ADRA1A (0.46) | ADRA1A | |
| SCHEMBL28286738 | 0.82 | SLC18A3 (0.61) | SLC18A3KCNH2HRH3 | |
| SCHEMBL29501422 | 0.81 | SLC18A3 (0.48) | ADRA1ASLC18A3KCNH2HRH3KEAP1 | |
| SCHEMBL22418711 | 0.81 | ADRA1A (0.61) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330009-B | Azacyclic compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-113330009-A | Nitrogen heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-30 | — | — | US | disclosed |
| WO-2020165031-A1 | SUBSTITUTED ISOQUINOLINE-PIPERIDINYLMETHANONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-20 | — | — | WO | disclosed |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-06-18 | — | — | US | disclosed |
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-24 | — | — | US | disclosed |
| US-9944621-B2 | Substituted piperidinyl tetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-17 | — | — | US | disclosed |
| US-9624198-B2 | Substituted piperidinyltetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141931-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885SLC18A3 2410/4885KCNH2 1264/4885 |
| US-20160318901-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 1852/4885SLC18A3 2280/4885KCNH2 1297/4885 |
| US-10323020-B2 | Substituted piperidinyl tetrahydroquinolines | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885SLC18A3 2410/4885KCNH2 1264/4885 |
| US-10961221-B2 | Substituted piperidinyl tetrahydroquinolines | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885SLC18A3 2410/4885KCNH2 1264/4885 |
| US-20180141930-A1 | SUBSTITUTED PIPERIDINYL TETRAHYDROQUINOLINES | TNNI3, TNNC1, TNNT2 | ADRA1A 2094/4885SLC18A3 2410/4885KCNH2 1264/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | ADRA1A 113/4885SLC18A3 2935/4885KCNH2 1270/4885 |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | TNNI3, TNNC1, PRPH | ADRA1A 1949/4885SLC18A3 2422/4885KCNH2 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.